A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.
|Articles|September 16, 2008
- April30 2003
- Volume 10
- Issue 8
VA HOME LOANS
Author(s)VA HOME LOANS
Advertisement
If you served in the military,Uncle Sam can help you buy a homewith no money down, via a loan fromthe US Department of Veterans Affairs(VA; 800-827-1000; www.homeloans.va.gov). A VA loan not onlyrequires no down payment, but alsocaps interest rates—and a lendercan't add more than 1 point to yourclosing costs. How much you canborrow, however, is limited to thevalue of the home as determined by aVA or Federal Housing Associationappraisal. If the seller wants morethan the appraised value, you mustcome up with the difference, either incash or through a secondary loan.The VA loan program is administeredby the home loan guaranteeservices of the Veterans BenefitsAdministration.
Articles in this issue
about 18 years ago
Portfolio CHECK-UPabout 18 years ago
Don't Delay, Start Saving for Retirementabout 18 years ago
Gain Perspective on Variable Annuitiesabout 18 years ago
Docs Miss the $ Boat-Againabout 18 years ago
Establish E-communication with Patientsabout 18 years ago
Enjoy E-mail Paydays for Consultationsabout 18 years ago
Confront HIPAA as a Former Soviet Wouldabout 18 years ago
Take Steps to Avoid IRS' Audit Dragnetabout 18 years ago
Take Fiscal Advice from a Fellow Doctorabout 18 years ago
Doc's Stocks Current StandingsAdvertisement
Related to this article
Volixibat reduced itch scores vs placebo in patients with PSC and moderate to severe pruritus in the phase 2b VISTAS trial presented at ACG 2026.
Topline phase 3 ALOFT-IPF data show admilparant 60 mg improved 52-week FVC vs placebo in IPF, while the 120 mg dose missed statistical significance.
Post hoc FORTIFY OLE analyses presented at ACG 2026 show sustained remission across disease locations and rising no-draining-fistula rates over 5 years.
Topline data show a 69% placebo-adjusted drop in serum bile acids, with an sNDA planned for the first half of 2027.
Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.
Phase 3 extension shows oral denifanstat sustains acne lesion reductions through 52 weeks, with 57% IGA success and 77% fewer inflammatory lesions.
Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.
Advertisement
Advertisement
Trending on HCPLive
1
GLP-1 Initiation in Heart Failure Reduces Pulmonary Artery Pressure, Hospitalizations
2
Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD
3
Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism
4
ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point
5